In a letter to the SEC (a document one might imagine written with a quill dipped in lemon juice), Scalar Gauge revealed it had sold every last crumb of its 399,717 shares in Five9 during the third quarter. The total value? A tidy sum calculated with the precision of a clockwork spider: $10.6 million, using the average price as a polite excuse to avoid specifics.
Let’s talk numbers, because what else really matters in this world, right? The Technology Select Sector SPDR Fund is, to be blunt, your old faithful friend. It’s got a low expense ratio of 0.08%, a track record stretching back nearly 30 years, and, yes, a collection of tech stocks like Nvidia and Apple, which seem to have been around since the dawn of time. But this isn’t a place for exciting new ventures. This fund tracks the S&P 500 tech sector, and with it, the stability of a phone number you’ve had for decades.
The fund, newly minted in the portfolio of Carmel, accounted for 1.9% of its $237.2 million in assets. A modest fraction, yet one that carried the weight of a decision made in the quiet hours of a market that rarely whispers its truths.
75,000 more. That totals 205,000 shares dispensed since August began-a steady bleed of paper, parcel by parcel, as if divesting not out of panic, but from a calm, methodical realization:
1-year price change calculated as of October 24, 2025.
Their holdings now constitute 1.88% of Monte’s 13F AUM, a figure that would make even the most jaded investor raise an eyebrow. Yet, as the adage goes, “The more things change, the more they remain the same.” Their top holdings-WFC, RTX, HSY, HD, and ABT-paint a picture of a fund as eclectic as a well-stocked library, though one wonders if the volumes are still in print.
Figures derived from the noble art of weighted averages ($60.31), and the sacred rite of market closure on October 27 ($60.09).
Consider the ledger:
The weighted average price-$5.76-suggests no desperation, merely the steady hand of a chessmaster moving pieces across a board where pawns become queens and queens become ghosts.
Trade direction: buy; position now represents 3.48% of the reported 13F assets under management. The long-term gambler watches, as the markets unfold like the slow march of time itself, witnessing new twists as old stakes are gradually raised.
According to a document filed with the Securities and Exchange Commission (a body whose primary purpose seems to be ensuring that paperwork remains the universe’s most enduring constant), Palisades had, during the third quarter, divested itself entirely of ADMA Biologics. This involved the sale of 398,647 shares, a number that sounds precise until you realize it’s roughly the population of a small island nation. The fund now holds precisely zero ADMA shares, a state of affairs as absolute as the heat death of the universe.